NCT04448223

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Multi Center, Randomized, Open-label, Active Controlled, Phase 2 Trial, Proof Of Concept Study to Evaluate the Efficacy and Safety of CKD-351 in Primary Open Angle Glaucoma or Ocular Hypertension Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351

Detailed description

Multi center, Randomized, Open-label, Active controlled, Phase 2 trial, Proof Of Concept Study to evaluate the efficacy and safety of CKD-351 in primary open angle glaucoma or ocular hypertension patients

Conditions

• Primary Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	CKD-351	Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
DRUG	Latanoprost+Dorzolmamide	Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day

Timeline

• Start date: 2020-06-11
• Primary completion: 2022-12-05
• Completion: 2022-12-05
• First posted: 2020-06-25
• Last updated: 2020-06-25

Locations

1 site across 1 country: South Korea